- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04538664
표피 성장 인자 수용체(EGFR) 엑손 20 삽입을 특징으로 하는 진행성 또는 전이성 비소세포폐암 환자를 대상으로 한 아미반타맙 및 카보플라틴-페메트렉시드 병용 요법에 대한 연구 (PAPILLON)
61186372NSC3001: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
연구 개요
상태
정황
연구 유형
등록 (실제)
단계
- 3단계
확장된 액세스
연락처 및 위치
연구 장소
-
-
-
Kaohsiung City, 대만, 807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Kaohsiung City, 대만, 833
- Chang Gung Medical Foundation
-
New Taipei City, 대만, 23561
- Taipei Medical University Shuang Ho Hospital
-
Taichung, 대만, 40447
- China Medical University Hospital
-
Taichung, 대만, 402
- Chung Shan Medical University Hospital
-
Taipei, 대만, 10002
- National Taiwan University Hospital
-
-
-
-
-
Busan, 대한민국, 48108
- Inje University Haeundae Paik Hospital
-
Gyeonggi-do, 대한민국, 10408
- National Cancer Center 1
-
Gyeongsangnam-do, 대한민국, 52727
- GyeongSang National University Hospital
-
Jeollanam-do, 대한민국, 58128
- Chonnam National University Hwasun Hospital
-
Seongnam-si, 대한민국, 13620
- Seoul National University Bundang Hospital
-
Seoul, 대한민국, 05505
- Asan Medical Center
-
Seoul, 대한민국, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, 대한민국, 06351
- Samsung Medical Center
-
Seoul, 대한민국, 03181
- Kangbuk Samsung Hospital
-
Seoul, 대한민국, 02841
- Korea University Anam Hospital
-
Seoul, 대한민국, 06591
- The Catholic University of Korea Seoul St Mary s Hospital
-
-
-
-
-
Bad Berka, 독일, 99437
- Zentralklinik Bad Berka GmbH
-
Berlin, 독일, 13125
- Evangelische Lungenklinik Berlin
-
Cologne, 독일, 50937
- Universitaetsklinikum Koeln
-
Cologne, 독일, 51109
- Kliniken der Stadt Koeln gGmbH
-
Gauting, 독일, 82131
- Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
-
Heidelberg, 독일, 69126
- Thoraxklinik am Universitatsklinikum Heidelberg
-
Heilbronn, 독일, 74072
- Onkologische Schwerpunktpraxis
-
Moers, 독일, 47441
- Bethanien Krankenhaus
-
Oldenburg, 독일, 26121
- Pius-Hospital Oldenburg
-
Recklinghausen, 독일, 45659
- Oncologianova GmbH
-
-
-
-
-
Irkutsk, 러시아 제국, 664035
- Irkutsk Regional Oncology Dispensary
-
Krasnogorsk, 러시아 제국, 143423
- Moscow City Oncology Hospital No 62
-
Krasnoyarsk, 러시아 제국, 660133
- Krasnoyarsk Regional Oncology Dispensary
-
Kuzmolovsky, 러시아 제국, 188663
- Leningrad Regional Oncology Dispensary
-
Moscow, 러시아 제국, 115533
- MCK
-
Nal'chik, 러시아 제국, 360000
- City Clinical Hospital #1
-
Nizhny Novgorod, 러시아 제국, 603000
- Nizhny Novgorod Regional Oncological Dispensary
-
Saint Petersburg, 러시아 제국, 197758
- N.N. Petrov Research Institute Of Oncology
-
Saint Petersburg, 러시아 제국, 194291
- Leningrad Regional Clinical Hospital
-
Saint Petersburg, 러시아 제국, 196006
- Oncology Medical Clinics AV Medical group
-
Tomsk, 러시아 제국, 634050
- Tomsk Cancer Research Institute
-
Ufa, 러시아 제국, 450083
- Bashkir State Medical University
-
Yaroslavl, 러시아 제국, 150054
- Yaroslavl Regional Clinical Oncology Hospital
-
-
-
-
-
George Town, 말레이시아, 10990
- Hospital Pulau Pinang
-
Johor Bahru, 말레이시아, 81100
- Hospital Sultan Ismail
-
Kuala Lumpur, 말레이시아, 50586
- Hospital Kuala Lumpur
-
Kuala Lumpur, 말레이시아, 59100
- University Malaya Medical Centre
-
-
-
-
-
Chihuahua City, 멕시코, 31217
- Centro Oncologico de Chihuahua
-
Guadalajara, 멕시코, 44280
- Hospital Civil de Guadalajara Fray Antonio Alcalde
-
Mexico City, 멕시코, 14080
- Instituto Nacional de Cancerologia
-
Mexico City, 멕시코, 14050
- Médica Sur
-
Mexico City, 멕시코, 03100
- Mexico Centre for Clinical Research, S.A. de C.V.
-
Monterrey, 멕시코, 64710
- i Can Oncology Center
-
México, 멕시코, 03100
- Health Pharma Professional Research
-
Naucalpan, 멕시코, 53100
- Oncologia Integral Satelite
-
-
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope 2
-
Orange, California, 미국, 92868
- University of California Irvine
-
Santa Monica, California, 미국, 90404
- UCLA
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20007
- Georgetown University Hospital
-
-
Florida
-
Tampa, Florida, 미국, 33612
- H. Lee Moffitt Cancer & Research Institute
-
-
Georgia
-
Athens, Georgia, 미국, 30607
- University Cancer And Blood Center LLC
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- Henry Ford Hospital
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- Washington University Medical Center
-
-
New Jersey
-
East Brunswick, New Jersey, 미국, 08816
- Regional Cancer Care Associates LLC
-
-
New York
-
New York, New York, 미국, 10032
- Columbia University Medical Center
-
New York, New York, 미국, 10016
- Langone Health at NYC University, NYU School of Medicine
-
-
Oregon
-
Portland, Oregon, 미국, 97213
- Providence Portland Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57104
- Sanford Health
-
-
Texas
-
Tyler, Texas, 미국, 75702
- Texas Oncology Pa
-
-
Utah
-
Salt Lake City, Utah, 미국, 84106
- Utah Cancer Specialists
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- Virginia Cancer Specialists
-
Salem, Virginia, 미국, 24153
- Blue Ridge Cancer Care
-
-
-
-
-
Leuven, 벨기에, 3000
- UZ Leuven
-
Roeselare, 벨기에, 8800
- Algemeen Ziekenhuis Delta
-
Yvoir, 벨기에, 5530
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Barretos, 브라질, 14784-400
- Fundacao Pio XII
-
Belo Horizonte, 브라질, 30110-017
- Cetus Oncologia
-
Florianópolis, 브라질, 88020-210
- Ynova Pesquisa Clinica
-
Ijuí, 브라질, 98700-000
- Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
-
Natal, 브라질, 59062 000
- Liga Norte Riograndense Contra O Cancer
-
Pelotas, 브라질, 96020 080
- UPCO Unidade de Pesquisa Clinica em Oncologia
-
Porto Alegre, 브라질, 90020-090
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, 브라질, 90610-000
- Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
-
Rio de Janeiro, 브라질, 22 250 905
- Oncoclinicas Rio de Janeiro S A
-
Rio de Janeiro, 브라질, 22281 100
- Instituto D Or de Pesquisa e Ensino IDOR
-
Rio de Janeiro, 브라질, 20231 050
- Ministerio da Saude Instituto Nacional do Cancer
-
Sorocaba, 브라질, 18030-075
- IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
-
São Paulo, 브라질, 04014-002
- Núcleo de Pesquisa São Camilo
-
São Paulo, 브라질, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, 브라질, 01246 000
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
Vitória, 브라질, 29308-014
- Hospital Evangélico de Cachoeiro de Itapemirim
-
-
-
-
-
A Coruña, 스페인, 15006
- Hosp Univ A Coruna
-
Badalona, 스페인, 08916
- Inst. Cat. D'Oncologia-Badalona
-
Barcelona, 스페인, 08025
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, 스페인, 08028
- Hosp. Univ. Quiron Dexeus
-
Barcelona, 스페인, 08035
- Hosp Univ Vall D Hebron
-
Burgos, 스페인, 09003
- Hosp. Univ. de Burgos
-
Madrid, 스페인, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, 스페인, 28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid, 스페인, 28046
- Hosp. Univ. La Paz
-
Madrid, 스페인, 28007
- Hosp. Gral. Univ. Gregorio Maranon
-
Majadahonda, 스페인, 28222
- Hosp. Univ. Pta. de Hierro Majadahonda
-
Málaga, 스페인, 29010
- Hosp Virgen de La Victoria
-
Pamplona, 스페인, 31008
- Clinica Univ. de Navarra
-
Seville, 스페인, 41013
- Hosp. Virgen Del Rocio
-
Zaragoza, 스페인, 50009
- Hosp. Clinico Univ. Lozano Blesa
-
-
-
-
-
Edinburgh, 영국, EH4 2XU
- Edinburgh Cancer Centre Western General
-
London, 영국, SW3 6JJ
- The Royal Marsden NHS Trust Chelsea
-
Sutton, 영국, SM2 5PT
- The Royal Marsden NHS Trust Sutton
-
-
-
-
-
Dnipro, 우크라이나, 49102
- Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
-
Kyiv, 우크라이나, 02091
- Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
-
Kyiv, 우크라이나, 03022
- National Cancer Institute
-
-
-
-
-
Jerusalem, 이스라엘, 91031
- Shaare Zedek Medical Center
-
Jerusalem, 이스라엘, 9112001
- Hadassah Medical Center
-
Kfar Saba, 이스라엘, 44281
- Meir Medical Center
-
Petah Tikva, 이스라엘, 49100
- Rabin Medical Center
-
Tel Aviv, 이스라엘, 6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bologna, 이탈리아, 40138
- A O U Sant Orsola Malpighi
-
Catania, 이탈리아, 95123
- Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
-
Meldola, 이탈리아, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Milan, 이탈리아, 20132
- IRCCS Ospedale San Raffaele
-
Milan, 이탈리아, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, 이탈리아, 20122
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Monza, 이탈리아, 20052
- San Gerardo Hospital
-
Ravenna, 이탈리아, 48121
- Ospedale S. Maria Delle Croci
-
Roma, 이탈리아, 00168
- Irccs Gemelli
-
Rozzano, 이탈리아, 20089
- Istituto Clinico Humanitas
-
-
-
-
-
Hyderabad, 인도, 500034
- Basavatarakam Indo-American Hospital
-
Kolkata, 인도, 700160
- Tata Medical Center
-
Mumbai, 인도, 400012
- Tata Memorial Hospital
-
Nashik, 인도, 422002
- HCG Manavta Cancer Centre
-
New Delhi, 인도, 110085
- Rajiv Gandhi Cancer Institute & Research Centre
-
Pune, 인도, 411013
- Noble Hospital Pvt Ltd
-
-
-
-
-
Bunkyō City, 일본, 113 8431
- Juntendo University Hospital
-
Hidaka, 일본, 350-1298
- Saitama Medical University International Medical Center
-
Himeji, 일본, 670-8520
- National Hospital Organization Himeji Medical Center
-
Hirakata, 일본, 573 1191
- Kansai Medical University Hospital
-
Kanazawa, 일본, 920 8641
- Kanazawa University Hospital
-
Kashiwa, 일본, 277 8577
- National Cancer Center Hospital East
-
Kishiwada, 일본, 596-8501
- Kishiwada City Hospital
-
Kobe, 일본, 650-0047
- Kobe City Medical Center General Hospital
-
Kurashiki, 일본, 710-8602
- Kurashiki Central Hospital
-
Kurume, 일본, 830-0011
- Kurume University Hospital
-
Matsusaka, 일본, 515-8544
- Matsusaka Municipal Hospital
-
Nagoya, 일본, 460-0001
- National Hospital Organization Nagoya Medical Center
-
Nagoya, 일본, 464 8681
- Aichi Cancer Center Hospital
-
Niigata, 일본, 951-8566
- Niigata Cancer Center Hospital
-
Osaka Sayama Shi, 일본, 589 8511
- Kindai University Hospital
-
Sagamihara, 일본, 252-0375
- Kitasato University Hospital
-
Sapporo, 일본, 060-8648
- Hokkaido University Hospital
-
Shiwa-gun, 일본, 028-3695
- Iwate Medical University Hospital
-
Shizuoka, 일본, 411 8777
- Shizuoka Cancer Center
-
Tokyo, 일본, 135 8550
- The Cancer Institute Hospital of JFCR
-
Toon-shi, 일본, 791-0295
- Ehime University Hospital
-
Wakayama, 일본, 641 8510
- Wakayama Medical University Hospital
-
Yamaguchi, 일본, 755-0241
- National Hospital Organization Yamaguchi Ube Medical Center
-
-
-
-
-
Beijing, 중국, 100142
- Beijing Cancer Hospital
-
Beijing, 중국, 100853
- Chinese PLA General Hospital
-
Beijing, 중국, 102206
- Peking University International Hospital
-
Beijing, 중국, 100142
- Beijing Cancer Hospital Chest Tumor Internal Medicine dept. II
-
Beijing, 중국, 101199
- Beijing Chest hospital, Capital medical university
-
Changchun, 중국, 130000
- Jilin cancer hospital
-
Changsha, 중국, 410013
- Hunan Cancer Hospital Chest Tumor Internal Medicine dept. II
-
Changsha, 중국, 410013
- Hunan Cancer hospital
-
Changzhou, 중국, 213003
- The First People's Hospital Of Changzhou
-
Chengdu, 중국, 610041
- West China Hospital Sichuan University
-
Chongqing, 중국, 400030
- Chongqing University Cancer Hospital
-
Fuzhou, 중국, 350001
- Fujian Medical University Union Hospital
-
Guangzhou, 중국, 510080
- The First Affiliated Hospital Sun Yat sen University
-
Hangzhou, 중국, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, 중국, 310009
- The Second Affiliated Hospital of Zhejiang University College of Medicine
-
Hangzhou, 중국, 310003
- The First Affiliated Hospital Zhejiang University College of Medicine
-
Hangzhou, 중국, 310016
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou, 중국, 310009
- The Second Affiliated Hospital of Zhejiang University College of Medicine 1
-
Harbin, 중국, 150000
- Harbin medical university cancer hospital
-
Linhai, 중국, 317000
- Taizhou Hospital of Zhejiang Province
-
Nanjing, 중국, 210031
- Nanjing Drum Tower Hospital
-
Shanghai, 중국, 200030
- Shanghai Chest Hospital
-
Shanghai, 중국, 200032
- Fudan University Shanghai Cancer Center
-
Shanghai, 중국, 200433
- Shanghai Pulmonary Hospital
-
Shanghai, 중국, 200123
- Shanghai East Hospital
-
Shenyang, 중국, 110004
- Shengjing Hospital Of China Medical University
-
Shenzhen, 중국, 518116
- Cancer hospital Chinese Academy of Medical Sciences, Shenzhen Center
-
Tianjin, 중국, 300052
- Tianjin Medical University General Hospital
-
Weifang, 중국, 261000
- Weifang People's Hospital
-
Wuhan, 중국, 430030
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
-
Wuxi, 중국, 214122
- Hospital of Jiangnan University
-
Xi'an, 중국, 710061
- The First Affiliated Hospital of Xian Jiaotong University
-
Yantai, 중국, 264000
- Yantai Yuhuangding Hospital
-
Zhengzhou, 중국, 450008
- Henan Cancer Hospital
-
-
-
-
Ontario
-
Ottawa, Ontario, 캐나다, K1H 8L6
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, 캐나다, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, 캐나다, H4A 3J1
- McGill University Health Centre
-
-
-
-
-
Bangkok, 태국, 10700
- Siriraj Hospital
-
Bangkok, 태국, 10400
- Phramongkutklao Hospital and Medical College
-
Songkhla, 태국, 90110
- Songklanagarind Hospital, Prince of Songkla University
-
-
-
-
-
Adana, 터키 (Türkiye), 01060
- Adana City Hospital
-
Adana, 터키 (Türkiye), 01250
- Başkent University Medical Faculty Adana Application and Research Center
-
Ankara, 터키 (Türkiye), 6560
- Gazi University Hospital
-
Ankara, 터키 (Türkiye), 6800
- Ankara Bilkent City Hospital
-
Edirne, 터키 (Türkiye), 22030
- Trakya University Medical Faculty
-
Istanbul, 터키 (Türkiye), 34722
- Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
-
Istanbul, 터키 (Türkiye), 34098
- Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
-
Istanbul, 터키 (Türkiye), 34214
- Medipol Mega University Hospital
-
Izmir, 터키 (Türkiye), 35580
- Izmir Medical Park Hospital
-
-
-
-
-
Lisbon, 포르투갈, G1R 2J6
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon, 포르투갈, 1998-018
- Hosp. Cuf Descobertas
-
Porto, 포르투갈, 4200-072
- Instituto Portugues de Oncologia
-
Porto, 포르투갈, 4099-001
- Centro Hospitalar Universitario do Porto, EPE
-
Vila Nova de Gaia, 포르투갈, 4434 502
- Centro Hospitalar de Vila Nova de Gaia Espinho E P E
-
-
-
-
-
Bydgoszcz, 폴란드, 85 796
- Centrum Onkologii im Prof F Lukaszczyka
-
Gdansk, 폴란드, 80 214
- Uniwersyteckie Centrum Kliniczne
-
Gdynia, 폴란드, 81 519
- Szpitale Pomorskie Sp z o o
-
Olsztyn, 폴란드, 10-357
- Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
-
Poznan, 폴란드, 60-693
- Private Specialist Hospitals - MedPolonia
-
Warsaw, 폴란드, 02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
-
-
-
-
Rio Piedras, 푸에르토 리코, 00935
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Bordeaux, 프랑스, 33000
- Institut Bergonie
-
Bron, 프랑스, 69500
- Hospices Civils de Lyon HCL
-
Dijon, 프랑스, 21000
- Centre Georges Francois Leclerc
-
Le Mans, 프랑스, 72037
- Centre Hospitalier Le Mans
-
Lille, 프랑스, 59037
- CHR Hôpital Calmette
-
Nantes, 프랑스, 44093
- CHU Nantes - Hopital Nord Laënnec
-
Paris, 프랑스, 75005
- Institut Curie
-
Pessac, 프랑스, 33604
- CHU Bordeaux
-
Saint-Mandé, 프랑스, 94163
- HIA Begin
-
-
-
-
-
Budapest, 헝가리, H-1529
- Orszagos Koranyi Tbc es Pulmonologiai Intezet
-
Gyöngyös, 헝가리, 3233
- Mátrai Gyógyintézet-Bronchológia
-
Szombathely, 헝가리, 9700
- Markusovszky Egyetemi Oktatokorhaz
-
Székesfehérvár, 헝가리, 8000
- Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
-
Törökbálint, 헝가리, 2045
- Tudogyogyintezet Torokbalint
-
-
-
-
-
Camperdown, 호주, 2050
- Chris O'Brien Lifehouse
-
Kogarah, 호주, 2217
- St George Hospital
-
Malvern, 호주, 3144
- Cabrini Medical Centre
-
Nedlands, 호주, 6009
- Sir Charles Gairdner Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation
- Participant must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Participant must agree to genetic characterization of tumor status through the required pretreatment tumor biopsy (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream
- A female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
Exclusion Criteria:
- Participant has evidence of synchronous NSCLC disease (as suggested by genetic characterization or radiographic appearance)
- Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to randomization is eligible)
- Participant has history of spinal cord compression that has not been treated definitively with surgery or radiation
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD, or radiation pneumonitis
- Participant has a contraindication to the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of hypersensitivity to, or cannot take, vitamin B12 or folic acid
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm A: Amivantamab + Chemotherapy
Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. |
Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
다른 이름들:
Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase. Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle. Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase. |
|
실험적: Arm B: Chemotherapy Alone
Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. |
Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase. Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle. Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
기간: From randomization to either disease progression or death whichever occurs first (up to 29 months)
|
PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (>=)20 percent (%) and >=5 millimeter (mm) from nadir (including baseline if it was smallest sum). |
From randomization to either disease progression or death whichever occurs first (up to 29 months)
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
객관적 반응률(ORR)
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
응답 기간(DoR)
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
전체 생존(OS)
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
후속 치료까지의 시간(TST)
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
첫 번째 후속 치료 후 무진행 생존(PFS2)
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
증상 진행까지의 시간(TTSP)
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
참가자 수 치료로 인한 부작용(TEAE)
기간: 1일부터 5년 2개월
|
1일부터 5년 2개월
|
|
심각도가 있는 참가자 수 TEAE
기간: 1일부터 5년 2개월
|
1일부터 5년 2개월
|
|
임상 검사실 이상이 있는 참가자 수
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
활력징후 이상이 있는 참가자 수
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
신체검사 이상 참가자 수
기간: 최대 5년 3개월
|
최대 5년 3개월
|
|
아미반타맙의 혈청 농도
기간: 1일차(사이클 1, 2, 3, 5, 7, 9, 11, 13), 2일차(사이클 1)
|
1일차(사이클 1, 2, 3, 5, 7, 9, 11, 13), 2일차(사이클 1)
|
|
항-아미반타맙 항체를 가진 참가자 수
기간: 1일차(사이클 1, 2, 3, 5, 7, 9, 11, 13), 2일차(사이클 1)
|
1일차(사이클 1, 2, 3, 5, 7, 9, 11, 13), 2일차(사이클 1)
|
|
유럽 암 연구 및 치료 기관의 삶의 질 설문지 핵심 30(EORTC-QLQ-C30)의 기준선 변경
기간: 기준일부터 5년 3개월까지
|
기준일부터 5년 3개월까지
|
|
환자 보고 결과 측정 정보 시스템-신체 기능(PROMIS-PF)의 기준선 대비 변화
기간: 기준일부터 5년 3개월까지
|
기준일부터 5년 3개월까지
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
간행물 및 유용한 링크
일반 간행물
- Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourao Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21.
- Sanborn RE, Zhou C, Tang KJ, Cho BC, Cheng S, Popat S, Ono A, Lu S, Majem M, Aguilar A, Del Rosario Garcia Campelo M, Hayashi H, Lee KY, Lee SH, Delmonte A, Alatorre-Alexander J, Richardson G, Santos V, Dooms C, Sabari JK, Shu CA, Girard N, Mansfield AS, Park K, Xia Y, Bhattacharya A, Buyukkaramikli N, Perualila N, Diels J, Acharya S, Chandler C, Proskorovsky I, Dearden L, Wortman-Vayn H, Mahadevia PJ, Knoblauch RE, Agrawal T, Baig M, Felip E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Target Oncol. 2025 Nov;20(6):979-989. doi: 10.1007/s11523-025-01182-0. Epub 2025 Nov 3.
- Kitazono S, Ono A, Kawamura T, Hataji O, Tanaka H, Matsumoto S, Watanabe N, Nagashima H, Oki M, Takahashi M, Anazawa T, Shirai T, Yamashita A, Wortman-Vayn H, Bhattacharya A, Agrawal T, Baig M, Knoblauch RE, Hayashi H. Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC. Cancer Sci. 2025 Nov;116(11):3139-3148. doi: 10.1111/cas.70180. Epub 2025 Sep 8.
- Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, CIl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC. Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis. Lung Cancer. 2026 Mar;213:109302. doi: 10.1016/j.lungcan.2026.109302. Epub 2026 Feb 2.
- Tang K, Wu F, Yang F, Yao Y, Zhao Y, Zhou J, Sun P, Wang D, Lv D, Wang H, Hu Y, Li Q, Song Y, Gao G, Pan F, Bhattacharya A, Baig M, Lorenzini PA, Wortman-Vayn H, Agrawal T, Zhou C. Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial. Chin Med J (Engl). 2026 May 26. doi: 10.1097/CM9.0000000000004134. Online ahead of print.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CR108850
- 61186372NSC3001 (기타 식별자: Janssen Research & Development, LLC)
- 2023-506033-29-00 (레지스트리 식별자: EUCT number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .